ArticleScientific reports2026
Prior pulmonary tuberculosis deteriorated all-cause mortality in AECOPD patients after discharge.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Chronic obstructive pulmonary disease (COPD) patients who have a history of pulmonary tuberculosis (PTB) often present with worse dyspnea and more acute exacerbations (AEs). However, the impact of prior PTB on prognosis in AECOPD patients remains to be further investigated. The diagnosis of patients with prior PTB was based on a combination of imaging and prior tuberculosis history. This study compared the clinical characteristics and prognosis of the Chinese AECOPD inpatients with or without prior PTB, and discussed the role of glucocorticoids in the prognosis of AECOPD patients with prior PTB by Kaplan-Meier analysis and Cox Regression analysis. 740 inpatients enrolled, and 231 patients (31.2%) were considered as the PTB group. The PTB group had obviously higher 1-year mortality (19.4% vs. 10.7%, P = 0.003) and long-term mortality (47.6% vs. 33.3%, P = 0.001) after discharge. Moreover, discharged AECOPD patients were defined as group E in the stable stage, and these group E patients with prior PTB using inhaled corticosteroid (ICS) during the stable stage were found to have lower mortality than those who did not use ICS after discharge. The predictors of ICS use decreasing all-cause mortality among these E group patients with PTB included patient characteristics, and CAT ≥ 20 was the strongest predictor (HR, 0.043; 95% CI, 0.006-0.331; P < 0.01). In this study, more than 30% of AECOPD patients had prior PTB, and the mortality of discharged AECOPD patients with prior PTB was significantly greater than that of those without. Surprisingly, ICS use during the stable stage appears to be associated with improved survival in discharged AECOPD patients who had prior PTB, and the strongest predictors of the association were CAT ≥ 20.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.